Drug Profile
Dezamizumab - GSK
Alternative Names: GSK-2398852Latest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator Pentraxin Therapeutics
- Developer GSK
- Class Monoclonal antibodies
- Mechanism of Action Serum amyloid P component inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Amyloidosis
Most Recent Events
- 04 Mar 2021 No development reported - Phase-I for Amyloidosis (Combination therapy) in Sweden (IV)
- 04 Mar 2021 No development reported - Phase-II for Amyloidosis (Combination therapy) in United Kingdom (IV)
- 04 Mar 2021 No development reported - Phase-II for Amyloidosis (Combination therapy) in USA (IV)